Abbott Labs | StockChase
106
Abbott Labs (ABT-N)

Last Price Recorded: $55.5600 on 2017-11-17

ON STOCKCHASE SINCE Jan 2001

biotechnology/pharmaceutical

Abbott Labs


Signal Opinion Expert

2012-07-09

COMMENT
Abbott Labs (ABT-N)
Will be splitting the company into 2 parts, pharma side and medical devices. Purchased a generic company out of India last year and India will be providing health care to the general population but will only pay for generic drugs . Currently within a couple of dollars of her target price so she might shave some of her holdings.
biotechnology/pharmaceutical
Christine Poole

CEO & Managing Director, GlobeInvest Capital Management

Price: $65.610
Owned: Yes

2010-01-13

TOP PICK
Abbott Labs (ABT-N)
Trading at about 13X earnings. Expects revenues to grow at 8%-10% and earnings to grow 12%-14%. 2.9% dividend. 7.5% free cash flow.
biotechnology/pharmaceutical
Gordon Reid

President, GoodReid Investment Counsel

Price: $55.290
Owned: Yes

2012-04-19

BUY
Abbott Labs (ABT-N)
This is a more of a growth company in the healthcare space. You are looking at higher single-digit growth and you are getting it for around 11-12 times PE. Nice dividend at around 3.4%.
biotechnology/pharmaceutical
Stan Wong

Director & Portfolio Manager, Private Wealth Management, ScotiaMcleod

Price: $59.510
Owned: No

2012-05-17

TOP PICK
Abbott Labs (ABT-N)
This has been one of the strong companies in the ethical drug companies. Have grown their dividend 10% at year over the last 10 years. Has been a very steady company. Traded sideways for 12 years in a price range and recently in the last year, broke out. They are going to split this company into a medical products/devices company and a pure pharma business. The pharma business will have a high yield attached and the other part has opportunities for efficiencies and growth.
biotechnology/pharmaceutical
David Burrows

President & Chief Investment Strategist, Barometer Capital Management

Price: $62.230
Owned: Yes

2010-05-27

DON'T BUY
Abbott Labs (ABT-N)
The model price is $48.13, a 2% upside only. Fully priced.
biotechnology/pharmaceutical
Brian Acker, CA

Chief Executive Officer, President and Chief Inves, Acker Finley Inc.

Price: $47.870
Owned: No

2011-10-19

HOLD
Abbott Labs (ABT-N)
The market likes the split. Going to split into pharma and medical space. 3.6% dividend. Hold on to it for the time being.
biotechnology/pharmaceutical
Stan Wong

Director & Portfolio Manager, Private Wealth Management, ScotiaMcleod

Price: $53.250
Owned: No

2012-03-15

TOP PICK
Abbott Labs (ABT-N)
Splitting itself into two businesses – Pharma and Infant nutrition. Couple of interesting acquisitions in the last year and a half. 3.6% yield.
biotechnology/pharmaceutical
Gavin Graham

Trustee, Pointbreak ETFs

Price: $59.110
Owned: Yes

2003-09-03

BUY
Abbott Labs (ABT-N)
Spinning off their hospital products division. A good strategy as there is not much growth. Not too expensive.
biotechnology/pharmaceutical
Brad Willock

Vice President and Senior Portfolio Manager, RBC Asset Management

Price: $41.750
Owned: Unknown

2011-10-20

BUY
Abbott Labs (ABT-N)
Restructuring came as a big surprise. Good valuation at 10X earnings. Long track record of raising dividends. Only real competition is Johnson & Johnson (JNJ-N) but feels this one has better growth. If they do the spinoff, they will probably stick with the non-pharma side of the business, which will be the better growth.
biotechnology/pharmaceutical
Barry Schwartz

CIO & Portfolio Manager, Baskin Wealth Management

Price: $54.050
Owned: Yes

2010-11-23

BUY
Abbott Labs (ABT-N)
Recently checked back. Well managed and in good financial shape.
biotechnology/pharmaceutical
Don Reed

President and Chief Executive Officer, Franklin Templeton Investments

Price: $46.950
Owned: Yes

2011-05-24

BUY
Abbott Labs (ABT-N)
Raised dividend 30+ years in a row. Is going to show 10% earnings growth over next 2-3 years. A good space. They got too cheap so there is an opportunity.
biotechnology/pharmaceutical
Barry Schwartz

CIO & Portfolio Manager, Baskin Wealth Management

Price: $53.330
Owned: Unknown

2001-12-10

BUY
Abbott Labs (ABT-N)
Pharmaceuticals may be re-establishing themselves for market leadership. Prefers Lily and Abbot
biotechnology/pharmaceutical
David Burrows

President & Chief Investment Strategist, Barometer Capital Management

Price: $55.500
Owned: Unknown

2005-08-25

DON'T BUY
Abbott Labs (ABT-N)
Pharmaceuticals is a group that has underperformed for about 3 years. This one, in relation to the rest of the group, has peformed better althoough all of them are retracing over the last couple of months. Prefers the bioceutical companies.
biotechnology/pharmaceutical
David Burrows

President & Chief Investment Strategist, Barometer Capital Management

Price: $45.110
Owned: No

2010-04-26

TOP PICK
Abbott Labs (ABT-N)
Pharma company. Nutritional division. Adult’s nutrition. Likes the diversification. Consistently increases dividend, about 3-1/2% at present. Recently beat numbers. Pulled earning back by 7%, but it is manageable.
biotechnology/pharmaceutical
Christine Poole

CEO & Managing Director, GlobeInvest Capital Management

Price: $50.370
Owned: Yes

2011-04-27

BUY
Abbott Labs (ABT-N)
Only a part of their business is in the pharma. Biggest drug is Humera for rheumatoid arthritis, which doesn’t go off patent until 2016. Also have a strong nutritional business. Earnings have grown every single year since 1991. Trades at about 11X earnings. Almost 4% dividend.
biotechnology/pharmaceutical
Gordon Reid

President, GoodReid Investment Counsel

Price: $52.180
Owned: Yes

Showing 1 to 15 of 106 entries
<< < 1 2 3 4 5 > >>

No Comments.


You must be logged in to comment.